Artificial oxygen carriers as red blood cell substitutes: A selected review and current status
Artificial oxygen carriers as red blood cell substitutes: A selected review and current status
复制标题
DOI：
10.1111/j.1525-1594.2004.07345.x
复制
发表时间：
2004-09-01
影响因子：
2.4
通讯作者：
Greenburg, AG
中科院分区：
文献类型：
--
作者：
Kim, HW;Greenburg, AG
在红细胞替代品（RCS）的开发中正在探索两种不同的方法：基于血红蛋白的氧载体（HBOCs）和基于全氟碳的氧载体（PFBOCs）。hboc是基于分子内和/或分子间“工程”的人或动物血红蛋白（Hbs），优化了O-2输送和更长的血管内循环。一些目前正在II/III期临床研究中进行评估。全氟氯化碳是全氟碳衍生物的水乳液，可溶解相对大量的O-2。基于60% （wt/vol）全氟辛基溴乳剂的PFBOC已在II/III期临床试验中进行了评估。虽然目前的PFBOC产品通常需要患者呼吸富含O-2的空气，但由于它们是完全合成的，因此具有一定的优势。本文简要介绍了RCS的基本原理、方法和发展现状。讨论了临床前和临床研究的结果，包括最近的II/III期临床研究。
Two distinct approaches are being explored in red blood cell substitute (RCS) development: hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based oxygen carriers (PFBOCs). HBOCs are based on intra- and/or intermolecularly "engineered" human or animal hemoglobins (Hbs), optimized for O-2 delivery and longer intravascular circulation. Some are currently being evaluated in Phase II/III clinical studies. PFBOCs are aqueous emulsions of perfluorocarbon derivatives that dissolve relatively large amounts of O-2. A PFBOC based on a 60% (wt/vol) emulsion of perfluorooctyl bromide has been evaluated in Phase II/III clinical trials. Although current PFBOC products generally require patients to breathe O-2 enriched air, they render certain advantages since they are totally synthetic. This article provides a short review of the basic principles, approaches, and current status of RCS development. Results of preclinical and clinical studies including recent Phase II/III clinical studies are discussed.